Pacific Biosciences of California Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $10.65 on 12/27/23, while the lowest value for the same period was recorded at $1.16 on 07/02/24.
52-week price history of PACB Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Pacific Biosciences of California Inc’s current trading price is -80.75% away from its 52-week high, while its distance from the 52-week low is 76.72%. The stock’s price range during this period has spanned from $1.16 to $10.65. In the Healthcare sector, the Pacific Biosciences of California Inc’s shares surpassed a trading volume of approximately 10.74 million for the day, which was noticeably higher compared to the average daily volume of 9.9.22 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Pacific Biosciences of California Inc (PACB) has experienced a quarterly decline of -5.75% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 558.69M and boasts a workforce of 796 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.6800, with a change in price of +0.2200. Similarly, Pacific Biosciences of California Inc recorded 8,802,798 in trading volume during the last 100 days, posting a change of +12.02%.
Examining PACB’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for PACB stands at 1.88. Similarly, the long-term debt-to-equity ratio is also 1.85.
PACB Stock Stochastic Average
Today’s raw stochastic average for Pacific Biosciences of California Inc over the last 50 days is 89.66%.This indicates a increase from the raw stochastic average of the past 20 days, which was 87.59%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 61.38% and 37.46%, respectively.
PACB Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Year to date metric has recorded a loss of -79.10%.However, over the last six months, we can see a stronger performance of -27.69%. Over the last 30 days, the price of PACB has fallen by 13.26%. And in the last five days, it has surged by 20.59%.
